We are live on
!
Find out more
PDM
Penn Davis McFarland Portfolio holdings
AUM
$1.12B
1-Year Est. Return
32.35%
This Fund
S&P 500
This Quarter
Est. Return
+11.33%
1 Year Est. Return
+32.35%
3 Year Est. Return
+86.8%
5 Year Est. Return
+114.42%
10 Year Est. Return
+392.43%
AUM
$337M
AUM Growth
+$17.5M
(+5.5%)
Cap. Flow
-$10.1M
Cap. Flow
% of AUM
-3%
Top 10 Holdings %
Top 10 Hldgs %
67.81%
Holding
53
New
9
Increased
13
Reduced
16
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$11.6M |
| 2 |
UnitedHealth
UNH
|
+$5.14M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$3.68M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$936K |
| 5 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$532K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$20.9M |
| 2 |
Gilead Sciences
GILD
|
+$7.58M |
| 3 |
NLSN
Nielsen Holdings plc
NLSN
|
+$2.28M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$529K |
| 5 |
NBL
Noble Energy, Inc.
NBL
|
+$410K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.75% |
| 2 | Energy | 17.25% |
| 3 | Communication Services | 16.89% |
| 4 | Healthcare | 13.49% |
| 5 | Industrials | 8.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alphabet (Google) Class C
GOOG
$4.32T
| $35.7M | 10.59% |
534,220
-8,200
| -2% | -$529K |
|
2
Enterprise Products Partners
EPD
$82.2B
| $28.9M | 8.56% |
1,024,864
+8,024
| +0.8% | +$217K |
|
|
3
Bristol-Myers Squibb
BMY
$124B
| $26.8M | 7.94% |
417,346
+201,695
| +94% | +$11.6M |
|
4
Qualcomm
QCOM
$180B
| $25M | 7.4% |
282,842
-4,138
| -1% | -$346K |
|
5
Kinder Morgan
KMI
$72.4B
| $23.4M | 6.94% |
1,104,915
+21,494
| +2% | +$435K |
|
6
Sprouts Farmers Market
SFM
$6.93B
| $21.2M | 6.28% |
1,094,872
-16,489
| -1% | -$319K |
|
|
7
Alphabet (Google) Class A
GOOGL
$4.33T
| $21M | 6.21% |
312,840
-4,300
| -1% | -$277K |
|
8
Apple
AAPL
$4.89T
| $20.4M | 6.04% |
277,656
-3,552
| -1% | -$229K |
|
|
NLSN
9
DELISTED
Nielsen Holdings plc
NLSN
| $13.7M | 4.05% |
673,129
-112,375
| -14% | -$2.28M |
|
|
ABB
10
DELISTED
ABB Ltd
ABB
| $12.8M | 3.78% |
529,785
-7,490
| -1% | -$160K |
|
|
ATVI
11
DELISTED
Activision Blizzard
ATVI
| $12.6M | 3.75% |
212,551
+66,448
| +45% | +$3.68M |
|
|
12
UnitedHealth
UNH
$384B
| $12.2M | 3.63% |
41,658
+19,648
| +89% | +$5.14M |
|
13
Xylem
XYL
$29.2B
| $12.1M | 3.58% |
153,426
-2,145
| -1% | -$167K |
|
14
Las Vegas Sands
LVS
$30.3B
| $11.4M | 3.4% |
165,825
-2,780
| -2% | -$173K |
|
15
Check Point Software Technologies
CHKP
$14.2B
| $10.8M | 3.21% |
97,419
-1,330
| -1% | -$149K |
|
16
eBay
EBAY
$49.2B
| $9.89M | 2.93% |
273,932
-2,208
| -0.8% | -$80K |
|
17
Accenture
ACN
$88.5B
| $9.44M | 2.8% |
44,827
-1,177
| -3% | -$229K |
|
|
INOV
18
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $8.76M | 2.6% |
465,224
-5,734
| -1% | -$96K |
|
|
19
Gilead Sciences
GILD
$169B
| $4.51M | 1.34% |
69,474
-116,417
| -63% | -$7.58M |
|
|
NBL
20
DELISTED
Noble Energy, Inc.
NBL
| $3.38M | 1% |
136,108
-19,286
| -12% | -$410K |
|
21
Honeywell
HON
$71.7B
| $2.21M | 0.66% |
13,259
+93
| +0.7% | +$15.2K |
|
22
NXP Semiconductors
NXPI
$68.3B
| $1.32M | 0.39% |
10,400
| – | – |
|
|
RETA
23
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.05M | 0.31% |
+5,131
| New | +$936K |
|
24
Visa
V
$694B
| $1.04M | 0.31% |
5,525
+1,125
| +26% | +$203K |
|
25
Matador Resources
MTDR
$6.59B
| $809K | 0.24% |
45,000
| – | – |
|
Similar funds
EC
JLBC
WA
FBFS
JAFL
SL
PTC
CT
Penn Davis McFarland's Q4 2019 Portfolio in Review
As of Q4 2019, Penn Davis McFarland held 53 positions worth $337M, up 5.5% from $320M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Penn Davis McFarland's Q4 2019 filing shows 9 new, 13 increased, 16 reduced and 4 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 5,131 shares worth $1.05M. The largest sale was Celgene Corp, an estimated $20.9M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 24% a quarter earlier, followed by Energy and Communication Services.
- Penn Davis McFarland's largest Q4 2019 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 5,131 shares worth $1.05M.
- Penn Davis McFarland added most to Bristol-Myers Squibb in Q4 2019, an estimated $11.6M increase.
- Penn Davis McFarland's biggest Q4 2019 reduction was Gilead Sciences, cutting an estimated $7.58M.
- Penn Davis McFarland fully exited Celgene Corp in Q4 2019, selling an estimated $20.9M.
- Penn Davis McFarland's ten largest holdings make up 68% of its $337M portfolio in Q4 2019.
- Penn Davis McFarland opened 9 new positions and closed 4 in Q4 2019.
- Penn Davis McFarland's portfolio value rose 5.5% quarter-over-quarter to $337M.
Based on Penn Davis McFarland's 13F filing for Q4 2019, filed 17 Jan 2020.